Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus THEOCLEAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus THEOCLEAR 80.
FORADIL vs THEOCLEAR-80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Inhibits phosphodiesterase, increasing cAMP levels, leading to bronchodilation and reduced airway inflammation.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/mL.
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator